These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

649 related items for PubMed ID: 19451504

  • 21. Hidradenitis suppurativa managed with adalimumab.
    Yamauchi PS, Mau N.
    J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
    [Abstract] [Full Text] [Related]

  • 22. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
    Lozeron P, Denier C, Lacroix C, Adams D.
    Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
    [Abstract] [Full Text] [Related]

  • 23. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 24. Long-term efficacy of infliximab in hidradenitis suppurativa.
    Paradela S, Rodríguez-Lojo R, Fernández-Torres R, Arévalo P, Fonseca E.
    J Dermatolog Treat; 2012 Aug; 23(4):278-83. PubMed ID: 22482700
    [Abstract] [Full Text] [Related]

  • 25. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 26. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.
    Reddick CL, Singh MN, Chalmers RJ.
    Dermatol Online J; 2010 Aug 15; 16(8):15. PubMed ID: 20804692
    [Abstract] [Full Text] [Related]

  • 27. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS.
    Am J Gastroenterol; 2009 Dec 15; 104(12):3042-9. PubMed ID: 19724267
    [Abstract] [Full Text] [Related]

  • 28. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.
    Haslund P, Lee RA, Jemec GB.
    Acta Derm Venereol; 2009 Nov 15; 89(6):595-600. PubMed ID: 19997689
    [Abstract] [Full Text] [Related]

  • 29. Interstitial keratitis secondary to severe hidradenitis suppurativa: a case report and literature review.
    Alzaga Fernandez AG, Demirci H, Darnley-Fisch DA, Steen DW.
    Cornea; 2010 Oct 15; 29(10):1189-91. PubMed ID: 20628295
    [Abstract] [Full Text] [Related]

  • 30. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.
    Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, Bachelez H, Morel P, Lebbé C.
    J Am Acad Dermatol; 2007 Apr 15; 56(4):624-8. PubMed ID: 17240478
    [Abstract] [Full Text] [Related]

  • 31. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD.
    J Am Acad Dermatol; 2014 Feb 15; 70(2):243-51. PubMed ID: 24314876
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD, Cannizzaro MV, Tartaglia C, Bianchi L.
    Clin Exp Dermatol; 2020 Jun 15; 45(4):438-444. PubMed ID: 31630436
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM, Gandra SR, Fox KM, Wilson KL.
    J Med Econ; 2012 Jun 15; 15(4):635-43. PubMed ID: 22332705
    [Abstract] [Full Text] [Related]

  • 38. Adalimumab: A Review in Hidradenitis Suppurativa.
    Kim ES, Garnock-Jones KP, Keam SJ.
    Am J Clin Dermatol; 2016 Oct 15; 17(5):545-552. PubMed ID: 27665300
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.